The TAMARIN study: tamoxifen for MPNs
Allogeneic transplant is not the quintessential treatment for ALL anymore!
Pros and cons of CML first-line therapy
When should we start treatment for relapsed multiple myeloma patients?
The future of lymphoma treatment – combining new therapies with molecular diagnosis